As the first of the baby boom generation reaches 75 this year, the financial reality of long-term care needs are moving front and center.
The president has sold soft infrastructure such as in child care, college and health as good for the economy, just like hard infrastructure such as roads and bridges. Some economists are skeptical.
The company applied in April for Food and Drug Administration approval to sell the new product. Now that process could take a bit more time.
Biogen and Ionis' approach to Lou Gehrig's disease flopped over the weekend, leading IONS stock to collapse to a five-year low Monday.
Bad news the company received today from the FDA surprised investors more than it probably should have.
Shares of the biotech companies are slumping after the failure of a trial for its treatment for amyotrophic lateral sclerosis.
Failing to enroll in Medicare can lead to some steep penalties, and that’s just as true for Medicare Part D, which covers prescription drugs. Eight in 10 Medicare beneficiaries were not aware of the late enrollment penalty for Part D, according to a survey of more than 1,000 people from MedicareAdvantage.com. The penalty applies to people who do not have “creditable drug coverage” for 63 days.
U.S. regulators 'will start moving [booster] recommendations to earlier ages,' predicts Albert Bourla.
Anavex Life Sciences and Affimed both sport unique drug development platforms that could be worth billions.
It looks like the gene therapy market is a haunted house, but growing biotech Repligen might be the treat investors need this Halloween.
Let’s talk a bit about return potential, and small-cap stocks. The two attributes are related, and frequently offer investors a fine combination of risk-reward ratio to emphasize the former. It’s the basic arithmetic behind finding a solid return potential. A small cap stock, one with a market value lower than $2 billion, will usually feature a relatively low share price – and when share price is low, even a small gain in absolute terms will quickly translate into a high-percentage return. Some
Are you looking for biotech stocks that could shoot higher? Wall Street analysts who cover the stocks on this list think they could provide some eye-popping gains. Every stock on this list has a consensus price target that's 91% above its present price.
Is Pfizer stock a buy after the CDC recommended Covid booster shots for people age 65 and older, and otherwise vulnerable Americans?
Coronavirus cases are receding nationwide—but not in every state. In fact, in some states in America, cases are actually rising quickly, as the virus lowers in former hotspots in the South. Where is COVID rising and how can you stay safe no matter where you live? Read on for the 5 states that have the fastest rising caseloads—and to ensure your health and the health of others, don't miss these Sure Signs You've Already Had COVID. 1 Vermont "Despite having the highest vaccination rates in the cou
What is considered middle class? Middle Class can vary by state and a range of incomes fall under middle class. Find out here if you are in the middle class.
The idea is to offer additional flexibility so that Americans in certain situations can receive booster doses of a different vaccine than they received for their initial dose.
One of the world’s largest and most important industries is ripe for disruption, and an under-the-radar artificial intelligence firm is ready to try its luck
“They still don’t know how it happened."
Expert panel of patient advocacy leaders on COVID-19, its impact on patients and moving forward
Over the past 10 years, U.S. stocks have delivered outstanding returns for investors. The major stock indices such as the Dow Jones Industrial Average, the NASDAQ Composite, and the S&P 500 have all climbed by more than 200% during this boom period. For example, biotech innovators Axsome Therapeutics (NASDAQ: AXSM) and Moderna (NASDAQ: MRNA), along with electric-car giant Tesla (NASDAQ: TSLA), have all generated well over 1,000% returns on capital for investors in just the past three years.
Poor people need insurance. Seniors need dental care. And there may not be money for both.